Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07585630 · ClinicalTrials.gov registry record · Phase 2
A1Cantus vs. Placebo
A Phase 2 study, sponsored by University of California, Riverside.
- Not yet
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT07585630: Clinical Trial Phase 2 study, sponsored by University of California, Riverside.
NCT07585630 is a Phase 2 study that has not yet begun recruiting, run by University of California, Riverside. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07585630, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, Riverside.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The investigators will conduct a randomized controlled 2-arm parallel trial of A1c Drink vs. Placebo over a 3-month period and compare changes in Ha1c from baseline to 3 months. Investigator and study personnel, as well as participants, will be blinded to drink assignments.
Primary Outcome
Change in Ha1c from baseline to 3 months. To test the efficacy of the A1Cantus drink in improving glycemic control in patients with Type II Diabetes
Interventions
- OTHER Placebo drink
- DIETARY_SUPPLEMENT A1C Drink
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 2 |
What is known before NCT07585630 opens enrollment
NCT07585630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo drink is the first listed.
NCT07585630 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07585630 about?
NCT07585630 is a clinical study titled "A1Cantus vs. Placebo". The investigators will conduct a randomized controlled 2-arm parallel trial of A1c Drink vs. Placebo over a 3-month period and compare changes in Ha1c from baseline to 3 months. Investigator and study personnel, as well as participants, will be blinded to drink assignments.
What is the current status of trial NCT07585630?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-06-15. Estimated completion is 2028-06-01.
What interventions are being tested in trial NCT07585630?
The interventions under investigation include: Placebo drink (OTHER), A1C Drink (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07585630?
This trial is sponsored by University of California, Riverside, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07585630's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI